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Abstract
Background: Dried blood spot samples (DBSS) from newborns are widely used in neonatal screening for selected metabolic
diseases and diagnostic possibilities for additional disorders are continuously being evaluated. Primary immunodeficiency
disorders comprise a group of more than one hundred diseases, several of which are fatal early in life. Yet, a majority of the
patients are not diagnosed due to lack of high-throughput screening methods.
Methodology/Principal Findings: We have previously developed a system using reverse phase protein microarrays for
analysis of IgA levels in serum samples. In this study, we extended the applicability of the method to include determination
of complement component C3 levels in eluates from DBSS collected at birth. Normal levels of C3 were readily detected in
269 DBSS from healthy newborns, while no C3 was detected in sera and DBSS from C3 deficient patients.
Conclusions/Significance: The findings suggest that patients with deficiencies of specific serum proteins can be identified
by analysis of DBSS using reverse phase protein microarrays.
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Introduction
Primary immunodeficiency disorders (PIDs) constitute a group
of inherited defects of the immune system with an estimated
prevalence of one in 500 in the United States [1]. Many of the
affected individuals are asymptomatic, but more severe defects
may result in a fatal outcome if untreated. Some patients show an
increased susceptibility to infections during the first years of life,
yet, a majority of them are not diagnosed during childhood due to
lack of suitable analytical methods. As many of the acquired
infections are severe, early diagnosis might prevent organ damage
or even death.
Defects of the complement system constitute one of the vastly
under-diagnosed PID groups [2]. The third component of
complement (C3) is the most abundant protein in the complement
system with serum levels of approximately 1 g/l in both adults and
newborns. It plays an important role in the clearing of infections as
it is involved in cytolysis, increased vasopermeability, opsonization,
clearance of immune complexes and facilitation of B cell
proliferation and differentiation. Individuals lacking C3 are
therefore highly susceptible to recurrent systemic bacterial
infections and frequently suffer from immune complex-related
disorders, such as glomerulonephritis and systemic lupus erythe-
matosus [3]. The deficiency is caused by mutations in the C3 gene,
resulting in absence/markedly reduced levels, or dysfunction of the
protein [4]. The disorder is rare, only 23 families (31 individuals)
have been identified to date [for review see 3,5–7] and ten
different, unique mutations have been found in the C3 encoding
gene [8–15]. In most cases, the defect is found in consanguineous
family and noted already in infancy or early childhood due to life-
threatening infections during the first year of life. Current
complement analysis in clinical practice is restricted to cases
where a patient’s health status is brought to attention, often due to
severe infections. Thus, an early diagnosis of complement
deficiency may decrease the risk of acquiring severe infections
during childhood by using prophylactic treatment.
In the 60s, neonatal screening programs for metabolic disorders,
such as phenylketonuria, based on the use of dried blood spot
samples (DBSS), were introduced in several countries. Today, they
constitute an established part of the neonatal healthcare system. In
Sweden, DBSS have been collected from all newborns and stored
since 1975. As reviewed by McDade et al, 2007, there is a growing
interest in the use of DBSS in large population-based biomarker
studies; the study of Tsunami Aftermath and Recovery being the
largest to date with 35 000 DBSS collected [16]. The DBSS have
also been used in multiplex analysis of inflammatory markers [17]
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Wisconsin launched a DBSS based newborn screening program
for severe combined immunodeficiency [18]. During 2008, all
children born in Wisconsin have been screened and it is
anticipated that several additional states will join the pilot
screening program during 2009.
In the present study, we investigated whether patients with C3
deficiency can be identified by the analysis of DBSS eluates using
reverse phase serum microarrays. This assay, previously described
by Janzi et al, 2005, provides a novel platform suitable for large-
scale, semi-quantitative determination of concentrations of serum
proteins [19].
Results
C3 levels in serum samples
C3 deficient sera from two non-related patients were used in this
study. Serum samples from twelve controls and the Swedish [20]
and Brazilian patients [21] were analysed for C3 levels by ELISA
and serum microarrays. No C3 was detected in the two C3
deficient patient samples, whereas both methods readily detected
C3 in all twelve control serum samples (varying from 0.7 to 1.2 g/
l), with a correlation of 0.83 (Figure 1).
Determination of elution procedure for DBSS
To determine the appropriate temperature and time of elution
for proteins from the DBSS, different conditions were tested using
12 simulated DBSS, prepared using a freshly collected adult blood
control sample containing 1.3 g/l. Each constructed DBSS
contained 15 ml of blood (approximately 9 ml of plasma) and the
samples were eluted in 4uC, room temperature, or 37uC, for one
hour, 24 hours, 48 hours or one week. The C3 levels were
determined by ELISA and a ratio between the original amounts of
C3 in the blood sample and the amounts obtained from the DBSS,
was calculated. The amount of C3 obtained when testing various
conditions ranged from 0.9 to 1.3 g/l, giving a ratio from 3:5
(37uC, one hour) to 1:1 (4uC, one week). To ensure effective
elution, the DBSS included in the study were thus eluted for one
week at 4uC.
C3 levels in DBSS
The storage time for the DBSS prior to elution and analysis was
20 years for the Swedish patient and 8–23 years for thirteen of the
controls. The remaining control DBSS had not been stored before
analysis. No C3 was detected in the DBSS eluate from the Swedish
patient using neither ELISA nor microarrays. In the control group
(n=269), C3 was readily detected in all samples, with a correlation
between the two methods of 0.49 (Figure 2). The mean C3 level of
0.6 g/l in the 13 stored controls was significantly lower (P,0.01)
than the mean level of 1.0 g/l in the freshly collected controls. The
levels of C3 in both control groups were significantly higher
(P,0.01) than in the C3 deficient patient sample, indicating that
both methods are suitable for identification of C3 deficiency using
DBSS eluates. The morphology of the microarray spots was
similar to those previously described [19] (Figure 3).
As no original DBSS was available from the Brazilian C3D
patient, a simulated DBSS was created by mixing serum from the
Brazilian patient and blood cells from the Swedish C3D patient.
Positive and negative controls were prepared in the same manner.
Simulated DBSS have been used in previous studies on PIDs [22].
Similar to the original DBSS of the Swedish patient, no C3 was
detected in the Brazilian DBSS or negative controls, while all 9
positive controls had detectable levels of C3 (P,0.01), using both
ELISA and serum microarrays (data not shown).
To determine the coefficient of variation (CV) for measuring C3
levels in DBSS using ELISA, we tested the C3 levels in 14
randomly selected DBSS from our collection of control samples at
four different occasions. The CV was 29613%, which was
significantly higher than that of the microarrays (1566%).
Figure 1. Correlation between serum microarrays and ELISA for C3 levels in serum samples. The correlation between serum microarray
intensities (arbitrary units) and C3 concentration (g/l) for serum samples from 12 controls (circles), Swedish C3 deficient patient (triangle) and Brazilian
C3 deficient patient (square).
doi:10.1371/journal.pone.0005321.g001
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Six control DBSS showed consistently low intensities on serum
microarrays but normal C3 levels on ELISA. The samples were
therefore re-printed together with the DBSS eluate of the Swedish
C3 deficient patient and 12 random, normal-intensity DBSS from
our collection of control samples and tested for serum IgG levels.
The intensities for all six low-intensity samples were comparable to
those of the positive controls (data not shown), indicating that the
samples were printed properly.
To investigate whether the six low-intensity samples contained
substances that affected the results of the microarrays, the samples
were mixed with normal-intensity DBSS eluates and C3 levels
were retested. The results indicate that the low-intensity samples
do not contain substances that affect the C3 analysis (data not
shown).
Subsequently, the protein content in the six samples was
determined by SDS-PAGE. A number of low molecular weight
bands were noted, suggesting degradation of serum proteins (data
not shown). No such bands were seen in the eluates from the C3
deficient patient or the normal-intensity controls, suggesting that
C3 is one of the degraded proteins in these samples.
Discussion
Today, a majority of PID patients are not diagnosed until
brought to attention due to recurrent and/or severe infections.
One of the reasons is the lack of high-throughput methods for
analysis. Complement deficiencies represent one of the vastly
under-diagnosed patient groups, with less than 10% of the affected
individuals having been identified in Sweden [2]. In this study, we
investigated whether C3 deficiency can be diagnosed in neonates
by microarray analysis of DBSS. Based on our results, we show
that C3 deficiency is present already at birth and it is possible to
identify the deficient individuals both by microarrays and
sandwich ELISA using DBSS eluates. Previously, we have used
microarrays for detection of C3 in serum samples [19] but to our
knowledge, this is the first study quantifying serum proteins eluted
from DBSS using this approach.
The DBSS are normally collected within 72 hours after birth
but can be stored for many years. The DBSS of the Swedish C3
deficient patient had been stored for 21 years prior to analysis. To
exclude that the long-time storage may have resulted in
degradation of the C3 protein, 13 DBSS stored for 8–23 years
were included in the control group. As C3 was detected in all
controls, we conclude that the lack of C3 in the patient sample is
not a result of protein degradation. The undetectable C3 levels in
the freshly collected serum sample from the C3 deficient patient
also support this notion.
In the present study, higher concentrations of primary and
secondary antibodies were required for microarray analysis of the
DBSS than for the serum samples. As the composition of the
DBSS eluates differs from that of the serum samples in terms of
total protein content and viscosity, these parameters may be
important for the piezo-electric printing procedure and might thus
influence the amount of the sample that is actually transferred to
the slide.
Figure 2. Correlation between serum microarrays and ELISA for C3 levels in DBSS. The correlation between serum microarray intensities
and ELISA values for the Swedish C3 deficient patient (green circle) and 269 controls. Six samples (marked in red) show low intensities on the
microarrays when compared to C3 concentration (g/l). The results for the low intensity samples are based on 6 printings and a total of 20–47
replicates.
doi:10.1371/journal.pone.0005321.g002
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theoretical sensitivity, originating from the small number of molecules
transferred to the arrays during printing. If 0.4 nl of a complex
sample, containing 1 g/l of a 180 kDa protein such as C3
(corresponding to 2.2 mM), is transferred to a slide, it will contain
approximately 1.3610
9 molecules of this particular protein. Since
only a fraction of the proteins present are available for detection, it is
inherent in the technology that low-abundant proteins will be difficult
to detect without proper signal amplification. With the present setup,
the limit of detection for C3 in serum is approximately 500 mg/l,
corresponding to 700 000 molecules. As the level of C3 in the
working dilution of DBSS (1:100) is approximately 10–20 mg/l, it is
thus a suitable protein for analysis with microarrays.
As there is a great need for a high-throughput screening for PIDs,
new approaches are currently being developed. In a recent study by
Ingvarsson et al, 2007, sandwich antibody microarrays were used
for multiplex analysis of eight complement proteins (including C3)
in unfractioned serum and plasma [23], showing promising results
for protein profiling in complex samples. However, the inherent
format of the sandwich antibody arrays rules out the simultaneous
screening of large numbers of samples that is required for
population screening. Another approach for identification of
immunodeficient patients was proposed by Chan & Puck in 2005,
involving screening for severe combined immunodeficiency [22].
The method is based on quantification of T-cell receptor excision
circles (TRECs) extracted from DBSS. The TRECs are generated
during normal development of T cells but as the patients have very
few, or no, T cells, no TRECs are produced. The authors detected
TRECs in 232 out of 239 healthy controls but none in patients with
severe combined immunodeficiency. The main drawback of this
method is that it only identifies patients with severe combined
immunodeficiency and some selected T cells disorders, comprising
less than 1% of all patients with PID. Furthermore, the lack of
detectable TRECs in the seven control samples probably represents
a high rate of false positives.
We believe that a large-scale screening should ideally be based
on the detection of one single analyte. As serum IgA levels are low
or absent in most of the patients with various forms of both
humoral and cellular PIDs, measurements of IgA levels in DBSS
may theoretically provide a basis for a neonatal screening
program. Another approach would be a multiplex array
comprising of antisera for all known PIDs. However, the primary
obstacle to such an approach is the present lack of suitable antisera
for many of the proteins involved in these defects.
The microarray technique we have developed enables testing of
thousands of samples simultaneously and the analysis can be
extended to include additional analytes by increasing the number
of slides used. Therefore, it represents an inexpensive and rapid
method for analysis of serum proteins, and thus identifying
patients with primary immunodeficiency lacking specific proteins.
Materials and Methods
Ethical statement
Approval for the study was obtained from the Regional Ethical
Review Board in Stockholm. The approval applied to all the
samples used in the work. Written consent was obtained when
collecting patient DBSS. All other samples are anonymized.
Figure 3. Visualization of the fluorescence intensitites of the microarrays. The upper part shows a subset of the 269 control DBSS. The
Swedish C3 deficient and C3 positive serum standards contains 23 serial dilutions each (high to low dilution, 1:5 to 1:100 000). The two lowest
dilutions of the standard curve are separated by a blank (PBS). The dotted rectangle depicts the C3 deficient sample.
doi:10.1371/journal.pone.0005321.g003
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Serum samples from an adult Swedish C3 deficient patient [20]
and twelve individuals with normal C3 levels were collected at the
department of Clinical Chemistry, KUS Huddinge, Sweden. A
serum sample from an adult Brazilian C3 deficient patient [21]
was collected at Laboratory of Complement, Department of
Immunology, Institute of Biomedical Sciences, University of Sa ˜o
Paulo, Sa ˜o Paulo, Brazil and lyophilized. Before use this C3
deficient serum was reconstituted in 100 ml of PBS.
Neonatal DBSS from the Swedish C3 deficient patient
(collected in 1985), 13 controls collected 1983–1998 and 256
freshly collected controls (2 dots, each 3 mm in diameter,
corresponding to approximately 3 ml plasma) were obtained from
the Center for Inherited Metabolic Diseases, Karolinska Univer-
sity Hospital Huddinge, Sweden. The 13 stored controls were
included to investigate the impact of storage on the C3 levels.
C3 levels in serum samples
Sandwich ELISA was performed for all serum samples using
polyclonal rabbit anti-human C3c antibodies (DAKO, Denmark)at a
final concentration of 3.8 mg/ml and horseradish peroxidase-
conjugated polyclonal goat anti-human C3c antibodies (Nordic
Immunological Laboratories, the Netherlands) at a final concentra-
tion of 3.3 mg/ml. The absorbance was read at 450 nm on a Vmax
microplate reader (Molecular Devices, USA). For determination of
C3 levels by microarrays, the serum samples were diluted 1:100 in
phosphate-buffered saline (PBS) with 0.5% Tween20 and printed
onto Epoxide slides (Corning, the Netherlands) using a non-contact
printing robot (Nano-plotter 2.0, Gesim, Germany), which deposits
approximately 0.4 nl/drop. The slides were blocked with SuperBlock
solution (Pierce Biotechnology, USA) and polyclonal rabbit anti-
human C3c antibodies (DAKO, Denmark) were added at a final
concentration of 115 ng/ml, followed by Alexa Fluor 555 conjugated
goat anti-rabbit IgG antibodies (Molecular Probes, USA) at a final
concentration of 33 ng/ml. The slides were scanned by a G2565BA
array scanner (Agilent, Palo Alto, CA, USA) and the image analysis
was performed with GenePixPro 5.1 (Axon Instruments, USA), using
non-circular feature alignment.
Preparation of simulated DBSS from the Brazilian C3D
serum sample
A volume of 25 ml of adult blood from the Swedish C3D patient
was centrifuged and added to 25 ml of the Brazilian serum sample.
A volume of 25 ml (corresponding to ,13 ml of plasma) of the
mixed sample was then transferred onto filter paper and left to dry
overnight. The filter paper was diluted 1:50 in PBS with 0.5%
Tween20 and soaked for one week at 4uC. The Swedish C3D
serum sample and 0.9% NaCl, mixed with 25 ml of blood cells
from the Swedish C3D patient, were used as negative controls and
9 serum samples with normal levels of C3 as positive controls. The
samples were tested using ELISA and serum microarrays.
C3 levels in DBSS
The DBSS from one Swedish C3 deficient patient, 256 freshly
collected controls and 13 controls stored 8–23 years (containing
approximately 3 ml of plasma), were soaked in 150 ml PBS with
0.5% Tween20, giving a final dilution of 1:50. The DBSS were
soaked for one week at 4uC and the C3 levels were determined by
sandwich ELISA (as described above). For microarrays, the DBSS
elutions were diluted to 1:100. Polyclonal rabbit anti-human C3c
antibodies (DAKO, Denmark) (2.3 mg/ml; 1:500), and Alexa
Fluor 555 conjugated goat anti-rabbit IgG antibodies (Molecular
Probes, USA) (1 mg/ml; 1:2,000) were used for detection. The
correlation analyses were performed using Microsoft Excel.
Serum IgG levels and total protein content of DBSS with
low serum C3 levels
Serum IgG levels were determined by microarrays using
polyclonal rabbit anti-human IgG (DAKO, Denmark) (83 ng/
ml) and Alexa Fluor 555 conjugated goat-anti-rabbit IgG
(Molecular Probes, USA) (33 ng/ml). An assessment of the protein
content was made using a SDS-polyacrylamide gradient gel
(NuPAGE 4–12% Bis-Tris pre cast gel, Invitrogen, USA).
MultiMark rainbow molecular weight marker (Invitrogen, USA)
was used as a standard and the gel was stained with Coomassie
Brilliant Blue. The low-intensity DBSS were compared to eluates
from DBSS of the Swedish C3 deficient patient and six random
DBSS showing normal C3 levels on microarrays.
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